These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 1980863)

  • 21. Management of anovulatory infertility.
    Crosignani PG; Bianchedi D; Riccaboni A; Vegetti W
    Hum Reprod; 1999 Sep; 14 Suppl 1():108-19. PubMed ID: 10573028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulsatile LHRH therapy for induction of ovulation in patients with hyperprolactinaemia and bromocriptine intolerance.
    Wilson JM; Atkinson AB; Sheridan B; Traub AI; Harley JM
    Ir J Med Sci; 1987 Aug; 156(8):232-5. PubMed ID: 3312084
    [No Abstract]   [Full Text] [Related]  

  • 23. Pulsatile GnRH therapy--an alternative successful therapy for induction of ovulation in infertile normo- and hyperprolactinaemic amenorrhoeic women with pituitary tumours.
    Bergh T; Skarin G; Nillius SJ; Wide L
    Acta Endocrinol (Copenh); 1985 Dec; 110(4):440-4. PubMed ID: 3911713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovulation triggers in anovulatory women undergoing ovulation induction.
    George K; Nair R; Tharyan P
    Cochrane Database Syst Rev; 2008 Jul; (3):CD006900. PubMed ID: 18646175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Medical treatment of hyperprolactinemic states using lisuride, a prolonged-action dopaminergic].
    Zárate A; Fonseca ME; Moran C; Miranda R
    Gac Med Mex; 1988; 124(3-4):107-9. PubMed ID: 2905312
    [No Abstract]   [Full Text] [Related]  

  • 26. Parity, pregnancy and neonatal outcomes in women treated for hyperprolactinaemia compared with a control group.
    Berinder K; Hulting AL; Granath F; Hirschberg AL; Akre O
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):393-7. PubMed ID: 17561983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of treatment with bromocriptine in patients with hyperprolactinaemia.
    al-Suleiman SA; Najashi S; Rahman J; Rahman MS
    Aust N Z J Obstet Gynaecol; 1989 May; 29(2):176-9. PubMed ID: 2803131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cabergoline: an advance in dopaminergic therapy.
    Bevan JS; Davis JR
    Clin Endocrinol (Oxf); 1994 Dec; 41(6):709-12. PubMed ID: 7889603
    [No Abstract]   [Full Text] [Related]  

  • 30. Quinagolide--a valuable treatment option for hyperprolactinaemia.
    Barlier A; Jaquet P
    Eur J Endocrinol; 2006 Feb; 154(2):187-95. PubMed ID: 16452531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observations with Bromocriptin tablet.
    Kovács I
    Ther Hung; 1992; 40(1):25-7. PubMed ID: 1585280
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hyperprolactinaemia and the regular menstrual cycle in asymptomatic women: should it be treated during therapy for infertility?
    Nawroth F
    Reprod Biomed Online; 2005 Nov; 11(5):581-8. PubMed ID: 16409707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment with a new non-ergot long-acting dopamine agonist, CV 205-502, in women with hyperprolactinaemia.
    Rasmussen C; Bergh T; Wide L; Brownell J
    Clin Endocrinol (Oxf); 1988 Sep; 29(3):271-9. PubMed ID: 2908030
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabergoline influences ovarian stimulation in hyperprolactinaemic patients with polycystic ovary syndrome.
    Papaleo E; Doldi N; De Santis L; Marelli G; Marsiglio E; Rofena S; Ferrari A
    Hum Reprod; 2001 Nov; 16(11):2263-6. PubMed ID: 11679501
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women.
    Giusti M; Lomeo A; Torre R; Sghedoni D; Mazzocchi G; Durante R; Giordano G
    Clin Endocrinol (Oxf); 1989 Mar; 30(3):315-21. PubMed ID: 2574083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The origin of hyperprolactinemia associated with infertility and its treatment with Bromocriptin-Richter tablets].
    Farkas M; Tárczy C; Tóth E
    Acta Pharm Hung; 1991 Sep; 61(5):262-76. PubMed ID: 1785356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome and long-term effects of pregnancy in women with hyperprolactinaemia.
    Ampudia X; Puig-Domingo M; Schwarzstein D; Corcoy R; Espinós JJ; Calaf-Alsina J; Webb SM
    Eur J Obstet Gynecol Reprod Biol; 1992 Sep; 46(2-3):101-7. PubMed ID: 1451886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up.
    Berinder K; Stackenäs I; Akre O; Hirschberg AL; Hulting AL
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):450-5. PubMed ID: 16181238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
    Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.